Abiomed’s Impella 2.5 Cardiac Assist Device Pumps Up Sales 75%
This article was originally published in The Gray Sheet
Executive Summary
Abiomed's June launch of its Impella 2.5 percutaneous cardiac assist device propelled the firm's sales ahead 75% to $20 million in its fiscal second quarter, ended Sept. 30